The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid

Kidney International

Volumn 68, Issue 2, 2005, Pages 474-486

  Khwaja, Arif ^b   Sharpe, Claire C ^b   Noor, Mazhar ^b   Kloog, Yoel ^b   Hendry, Bruce M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Farnesylthiosalicylic acid; Mesangial; Proliferation; Ras GTPases

Indexed keywords

FARNESYLTHIOSALICYLIC ACID; RAS PROTEIN; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FARNESOL; ONCOPROTEIN; PLASMA PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; SALICYLIC ACID DERIVATIVE;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL PROLIFERATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL CULTURE; CELL DIVISION; CELL MEMBRANE; CYTOLOGY; DRUG EFFECT; MESANGIUM; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD PROTEINS; CELL DIVISION; CELL MEMBRANE; CELLS, CULTURED; FARNESOL; GLOMERULAR MESANGIUM; HUMANS; MAP KINASE SIGNALING SYSTEM; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RAS PROTEINS; SALICYLIC ACIDS;

EID: 26944461271     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00425.x     Document Type: Article

References (40)

1. COUSER WG, JOHNSON RJ: Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 23:193-198, 1994
2. SCHOCKLMANN HO, LANG S, STERZEL RB: Regulation of mesangial cell proliferation. Kidney Int 56:1199-1207, 1999
3. JEFFERSON JA, JOHNSON RJ: Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 12:297-307, 1999
4. FLOEGE J, JOHNSON RJ, GORDON K, et al: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40:477-488, 1991
5. JOHNSON RJ, RAINES EW, FLOEGE J, et al: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175:1413-1416, 1992
6. FLOEGE J, ENG E, YOUNG BA, et al: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92:2952-2962, 1993
7. JOHNSON RJ: Cytokines, growth factors and renal injury: Where do we go now? Kidney Int 63(Suppl):S2-6, 1997
8. DOWNWARD J: Cell cycle: Routine role for Ras. Curr Biol 7:R258-260, 1997
9. DOWNWARD J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22, 2003
10. TAKAI Y, SASAKI T, MATOZAKI T: Small GTP-binding proteins. Physiol Rev 81:153-208, 2001
11. HIBI M, HIRANO T: Signal transduction through cytokine receptors. Int Rev Immunol 17:75-102, 1998
12. GUTKIND JS: Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. Oncogene 17:1331-1342, 1998
13. SINENSKY M: Recent advances in the study of prenylated proteins. Biochim Biophys Acta 1484:93-106, 2000
14. ROSKOSKI R, JR.: Protein prenylation: A pivotal posttranslational process. Biochem Biophys Res Commun 303:1-7, 2003
15. CHOY E, CHIU VK, SILLETTI J, et al: Endomembrane trafficking of ras: The CAAX motif targets proteins to the ER and Golgi [see comments]. Cell 98:69-80, 1999
16. HANCOCK JF, PATERSON H, MARSHALL CJ: A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63:133-139, 1990
17. MARCIANO D, BEN-BARUCH G, MAROM M, et al: Farnesyl derivatives of rigid carboxylic acids - Inhibitors of ras-dependent cell growth. J Med Chem 38:1267-1272, 1995
18. HAKLAI R, WEISZ MG, ELAD G, et al: Dislodgment and accelerated degradation of Ras. Biochemistry 37:1306-1314, 1998
19. MAROM M, HAKLAI R, BEN-BARUCH G, et al: Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270:22263-22270, 1995
20. ELAD G, PAZ A, HAKLAI R, et al: Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452:228-242, 1999
21. EGOZI Y, WEISZ B, GANA-WEISZ M, BEN-BARUCH G, KLOOG Y: Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 80:911-918, 1999
22. REIF S, WEIS B, AEED H, et al: The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally induced liver cirrhosis in rats. J Hepatol 31:1053-1061, 1999
23. KATZAV A, KLOOG Y, KORCZYN AD, et al: Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin Exp Immunol 126:570-577, 2001
24. CLARKE HC, KOCHER HM, KHWAJA A, et al: Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol 14:848-854, 2003
25. SHARPE CC, DOCKRELL ME, SCOTT R, et al: Evidence of a role for Ki-Ras in the stimulated proliferation of renal fibroblasts. J Am Soc Nephrol 10:1186-1192, 1999
26. JONES NC, FEDOROV YV, ROSENTHAL RS, OLWIN BB: ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. J Cell Physiol 186:104-115, 2001
27. BLOM IE, VAN DIJK AJ, WIETEN L, et al: In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 16:1139-1148, 2001
28. GESUALDO L, DI PAOLO S, MILANI S, et al: Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J Clin Invest 94:50-58, 1994
29. KLAHR S, MORRISSEY JJ: The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 75(Suppl):S7-14, 2000
30. KHWAJA A, O'CONNOLLY J, HENDRY BM: Prenylation inhibitors in renal disease. Lancet 355:741-744, 2000
31. MILLS GB, MOOLENAAR WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591, 2003
32. PAZ A, HAKLAI R, ELAD-SFADIA G, et al: Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20:7486-7493, 2001
33. WEISZ B, GIEHL K, GANA-WEISZ M, et al: A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579-2588, 1999
34. GANA-WEISZ M, HAKLAI R, MARCIANO D, et al: The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Commun 239:900-904, 1997
35. FRESNO VARA JA, CASADO E, DE CASTRO J, et al: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204, 2004
36. MOOLENAAR WH: Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253:230-238, 1999
37. SMALLEY KS, EISEN TG: Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 98:514-522, 2002
38. JANSEN B, SCHLAGBAUER-WADL H, KAHR H, et al: Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 96:14019-14024, 1999
39. ROSKOSKI R, JR.: STI-571: An anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309:709-717, 2003
40. GILBERT RE, KELLY DJ, MCKAY T, et al: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59:1324-1332, 2001